Pharmacokinetics of Tobramycin Administered at the Beginning of Intermittent Hemodialysis Session (ESRD Study)
Marjolaine Giroux(Hôpital Maisonneuve-Rosemont), Jean‐Philippe Lafrance(Université de Montréal), Denis Projean(Hôpital Maisonneuve-Rosemont), Jean-François Tessier(Hôpital Maisonneuve-Rosemont), Paul Gavra(Université de Montréal), Laurence Lepage(Hôpital Maisonneuve-Rosemont), Van Anh Sylvie Tran(Hôpital Maisonneuve-Rosemont), Lesly Lam(Hôpital Maisonneuve-Rosemont), Anik Henderson(Hôpital Maisonneuve-Rosemont), Nicolas Bouchard(Hôpital Maisonneuve-Rosemont), Georges Ouellet(Hôpital Maisonneuve-Rosemont), Michel Vallée
Cited by 2
Related Papers
Non-cystic Fibrosis Bronchiectasis
|Unknown|2012|254
Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial
|The Lancet|2022|236
Plasma Gelsolin and Its Association with Mortality and Hospitalization in Chronic Hemodialysis Patients
|Blood Purification|2017|164
Hemoperfusion for the Treatment of Poisoning: Technology, Determinants of Poison Clearance, and Application in Clinical Practice
|Seminars in Dialysis|2014|111
Guidelines for Diagnosis and Management of Infective Endocarditis in Adults
|JAMA Network Open|2023|108